Amicogen Inc (KQ:092040) — Market Cap & Net Worth
Market Cap & Net Worth: Amicogen Inc (092040)
Amicogen Inc (KQ:092040) has a market capitalization of $49.10 Million (₩72.45 Billion) as of June 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22015 globally and #1339 in its home market, demonstrating a 3.39% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amicogen Inc's stock price ₩1311.00 by its total outstanding shares 55266076 (55.27 Million). Review debt load of Amicogen Inc to assess the company's total debt and financial obligations.
Amicogen Inc Market Cap History: 2015 to 2026
Amicogen Inc's market capitalization history from 2015 to 2026. Data shows change from $564.24 Million to $49.10 Million (-21.13% CAGR).
Index Memberships
Amicogen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$270.08 Billion | 0.02% | #638 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$270.08 Billion | 0.02% | #638 of 1384 |
Weight: Amicogen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amicogen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amicogen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Amicogen Inc's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $379.14 Million | $68.97 Billion | $1.59 Billion | 0.01x | 0.24x |
| 2017 | $412.45 Million | $73.67 Billion | -$4.61 Billion | 0.01x | N/A |
| 2018 | $589.09 Million | $94.52 Billion | $40.17 Billion | 0.01x | 0.01x |
| 2019 | $439.66 Million | $115.18 Billion | $86.72 Million | 0.00x | 5.07x |
| 2020 | $663.38 Million | $115.86 Billion | $31.60 Billion | 0.01x | 0.02x |
| 2021 | $548.50 Million | $124.88 Billion | $3.73 Billion | 0.00x | 0.15x |
| 2022 | $335.14 Million | $144.30 Billion | -$47.22 Billion | 0.00x | N/A |
| 2023 | $283.14 Million | $159.90 Billion | -$23.29 Billion | 0.00x | N/A |
| 2024 | $144.57 Million | $173.60 Billion | -$52.79 Billion | 0.00x | N/A |
| 2025 | $66.74 Million | $41.98 Billion | -$29.96 Billion | 0.00x | N/A |
Competitor Companies of 092040 by Market Capitalization
Companies near Amicogen Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Amicogen Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Amicogen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Amicogen Inc's market cap moved from $564.24 Million to $ 49.10 Million, with a yearly change of -21.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩49.10 Million | -26.43% |
| 2025 | ₩66.74 Million | -53.83% |
| 2024 | ₩144.57 Million | -48.94% |
| 2023 | ₩283.14 Million | -15.52% |
| 2022 | ₩335.14 Million | -38.90% |
| 2021 | ₩548.50 Million | -17.32% |
| 2020 | ₩663.38 Million | +50.88% |
| 2019 | ₩439.66 Million | -25.37% |
| 2018 | ₩589.09 Million | +42.83% |
| 2017 | ₩412.45 Million | +8.79% |
| 2016 | ₩379.14 Million | -32.81% |
| 2015 | ₩564.24 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Amicogen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $49.10 Million USD |
| MoneyControl | $49.10 Million USD |
| MarketWatch | $49.10 Million USD |
| marketcap.company | $49.10 Million USD |
| Reuters | $49.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amicogen Inc
Amicogen, Inc. operates as an industrial biotechnology company in South Korea and internationally. The company develops, produces, and sells of enzymes and new materials; and produces food-related additives and health functional food. It manufactures and sells of biopharmaceutical materials and resins for purifying pharmaceutical proteins and health and beauty products. In addition, the company o… Read more